1,3-二烯丙基脲 | 1801-72-5

• 物质功能分类: 化学试剂 - 有机试剂 - 脲
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 1,3-二烯丙基脲
• 英文名称: 1,3-diallylurea
• 英文别名: diallylurea；N,N'-diallylurea；N,N'-Diallyl-harnstoff；1,3-di-(2-propenyl)-urea；1,3-bis(prop-2-enyl)urea
• CAS: 1801-72-5
• 化学式: C₇H₁₂N₂O
• mdl: MFCD00008639
• 分子量: 140.185
• InChiKey: QRWVOJLTHSRPOA-UHFFFAOYSA-N

物化性质

• 熔点：
  90-93 °C(lit.)
• 沸点：
  56°C/10mmHg(lit.)
• 密度：
  1.0897 (rough estimate)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• WGK Germany：
  3
• 海关编码：
  2924199090
• 安全说明：
  S24/25
• 储存条件：
  密封储存，应存放在阴凉干燥的库房中。

SDS

Name:	1 3-Diallylurea 99% Material Safety Data Sheet
Synonym:	None Known
CAS:	1801-72-5

Section 1 - Chemical Product MSDS Name:1 3-Diallylurea 99% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1801-72-5	1,3-Diallylurea	99%	217-291-7

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use agent most appropriate to extinguish fire.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1801-72-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white - waxy
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 90.00 - 93.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H12N2O
Molecular Weight: 140.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1801-72-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,3-Diallylurea - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 1801-72-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1801-72-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1801-72-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-二烯丙基脲 在 盐酸 、 对甲苯磺酸 作用下， 以 氯仿 、 水 为溶剂， 反应 5.0h， 生成 octaallylbambus[4]uril
  参考文献：
  名称：

  Extension of the Bambus[n]uril Family: Microwave Synthesis and Reactivity of Allylbambus[n]urils

  摘要：

  Microwave irradiations allow the preparation of unsaturated bambusurils in 85% yield compared to 20% yield under classical reaction conditions. Five new bambusurils were synthesized including unsaturated derivatives Allyl(8)BU[4] and Allyl(12)BU[6] bearing diallylglycoluril units. The reactivity of Allyl(8)BU[4] was tested in a variety of organic reactions showing that this macrocycle acts as a classical double bond-bearing product. The first monofunctionalized bambusuril Allyl(7)HepBU[4] prepared by a cross metathesis reaction is also reported.

  DOI：

  10.1021/ol303277u
• 作为产物：
  描述：

  天然芥菜籽油 在 lead(II) hydroxide on calcium carbonate 作用下， 生成 1,3-二烯丙基脲
  参考文献：
  名称：

  Rundqvist, Archiv der Pharmazie, 1898, vol. 236, p. 469

  摘要：

  DOI：

文献信息

• [EN] POLYCATIONIC AMPHIPHILES AND POLYMERS THEREOF AS ANTIMICROBIAL AGENTS AND METHODS USING SAME<br/>[FR] COMPOSÉS AMPHIPHILES POLYCATIONIQUES ET LEURS POLYMÈRES UTILISABLES EN TANT QU'AGENTS ANTIMICROBIENS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：WO2016172436A1

  公开（公告）日：2016-10-27

  The present invention includes novel polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes novel polymers of polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes methods useful for removing microorganisms and/or biofilm-embedded microorganisms from a surface. The present invention further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms and/or biofilm-embedded microorganisms on a surface.

  本发明包括新型的具有抗菌作用的多阳离子两性化合物。本发明还包括新型的多阳离子两性化合物聚合物，用作抗菌剂。本发明还包括用于从表面去除微生物和/或生物膜中嵌入的微生物的方法。本发明还包括用于预防或减少微生物和/或生物膜中嵌入的微生物在表面上生长或繁殖的组合物和方法。
• [EN] FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS<br/>[FR] DÉRIVÉS DE PYRIMIDINEDIONES FUSIONNÉS UTILISÉS COMME MODULATEURS DES RÉCEPTEURS TRPA1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2010109287A1

  公开（公告）日：2010-09-30

  The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl. Formula (I)

  本发明描述的是一类新颖的杂合吡啶二酮衍生物，其化学公式为（I），这些衍生物是TRPA（瞬时受体电位亚家族A）的调节剂。特别是，本文所述的化合物对于治疗或预防由TRPA1（瞬时受体电位亚家族A成员1）调控的疾病、状况和/或失调是有用的。本发明还提供了制备所述化合物、它们合成中使用的中间体、药物组合物以及治疗或预防由TRPA1调控的疾病、状况和/或失调的方法。公式（I）
• Modified amino acids, pharmaceuticals containing these compounds and method for their production
  申请人：——

  公开号：US20010036946A1

  公开（公告）日：2001-11-01

  The present invention relates to modified amino acids of general formula 1 wherein A, Z, X, n, m, R, R 2 , R 3 , R 4 and R 11 are defined as in claims 1 to 5 , their tautomers, their diastereomers, their enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them as well as their use for the production and purification of antibodies and as labelled compounds in RIA- and ELISA assays and as diagnostic or analytical aids in neurotransmitter research.

  本发明涉及一般式1的改良氨基酸，其中A、Z、X、n、m、R、R2、R3、R4和R11如权利要求1至5中所定义，它们的互变异构体、对映异构体、混合物及其盐，特别是其与无机或有机酸或碱的生理上可接受的盐，含有这些化合物的药物组合物，其用途以及用于制备它们的过程，以及它们在抗体的生产和纯化中的用途，以及在RIA和ELISA测定中作为标记化合物以及在神经递质研究中作为诊断或分析辅助工具的用途。
• NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE
  申请人：——

  公开号：US20030114422A1

  公开（公告）日：2003-06-19

  A compound having the formula 1 or a pharmaceutically acceptable salt thereof wherein R is hydrogen or hydroxy; R 1 is hydrogen, alkyl, arylalkyl, (CH 2 ) n OH, or (CH 2 ) NR 7 R 8 ; R 5 and R 6 are each independently hydrogen, halogen, NO 2 , CN, CF 3 , SO 2 NR 7 R 8 , PO 3 R 9 R 10 , alkyl, alkenyl, alkynyl, (CH 2 ) n CONR 7 R 8 , (CH 2 ) n CO 2 R 10 , NHCOR 11 , wherein R 7 and R 8 are each independently hydrogen or alkyl or together R 7 and R 8 form a ring of from three to seven atoms, R 9 is hydrogen or alkyl, R 10 is hydrogen or alkyl, R 11 is hydrogen or alkyl, and n is an integer of from zero to four; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b, and formed by the following bivalent radicals: a-NR 12 —CHR 13 —CHR 14 -b, a-CHR 13 —CHR 14 —NR 12 -b, a-CHR 13 —NR 12 —CHR 14 -b, a-CHR 14 —CH 2 —NR 12 —CHR 13 -b, a-CHR 13 —NR 12 —CH 2 —CHR 14 -b, a-CH 2 —CH 2 —CHR 13 —NR 12 -b, a-NR 12 —CHR 12 —CHR 13 —CH 2 —CH 2 -b, a-CH 2 —CH 2 —NR 12 —CH 2 —CH 2 -b, a-CH 2 —CH 2 —CH 2 NR 12 —CH 2 -b, a-CH 2 —NR 12 —CH 2 —CH 2 -b a-CH 2 —CH 2 —CH 2 —CH 2 —NR 12 -b, a-NR 12 —CH 2 —CH 2 —CH 2 —CH 2 -b, wherein R 12 is hydrogen, CH 2 CH 2 OH, or alkyl, and R 13 and R 14 are each independently hydrogen, CN, CONH 2 , CH 2 NH 2 , CH 2 OH, alkyl, arylalkyl, alkenyl, or CO 2 R 15 , wherein R 15 is hydrogen or alkyl. The compounds are useful in the treatment of disorders of mammals, responsive to the blockade of glutamic and aspartic acid receptors. Processes for preparing the compounds and novel intermediate useful in the processes are also included.

  具有以下式1的化合物或其药学上可接受的盐，其中R为氢或羟基；R1为氢、烷基、芳基烷基、(CH2)nOH或(CH2)NR7R8；R5和R6各自独立地为氢、卤素、NO2、CN、CF3、SO2NR7R8、PO3R9R10、烷基、烯基、炔基、(CH2)nCONR7R8、(CH2)nCO2R10、NHCOR11，其中R7和R8各自独立地为氢或烷基，或者一起形成由三至七个原子组成的环的R7和R8；R9为氢或烷基，R10为氢或烷基，R11为氢或烷基，n为从零到四的整数；A为与苯环在标记为a和b的位置融合的五至七个原子组成的环，并由以下二价基团形成：a-NR12—CHR13—CHR14-b，a-CHR13—CHR14—NR12-b，a-CHR13—NR12—CHR14-b，a-CHR14—CH2—NR12—CHR13-b，a-CHR13—NR12—CH2—CHR14-b，a-CH2—CH2—CHR13—NR12-b，a-NR12—CHR12—CHR13—CH2—CH2-b，a-CH2—CH2—NR12—CH2—CH2-b，a-CH2—CH2—CH2NR12—CH2-b，a-CH2—NR12—CH2—CH2-b，a-CH2—CH2—CH2—CH2—NR12-b，a-NR12—CH2—CH2—CH2—CH2-b，其中R12为氢、CH2CH2OH或烷基，R13和R14各自独立地为氢、CN、CONH2、CH2NH2、CH2OH、烷基、芳基烷基、烯基或CO2R15，其中R15为氢或烷基。这些化合物在治疗对谷氨酸和天冬氨酸受体阻滞有反应的哺乳动物的疾病中有用。还包括用于制备这些化合物的方法和在这些方法中有用的新中间体。
• Preparation of Mono-, Di-, and Trisubstituted Ureas by Carbonylation of Aliphatic Amines with <b><i>S</i></b>,<b><i>S</i></b>-Dimethyl Dithiocarbonate
  作者：Rita Fochi、Emma Artuso、Iacopo Degani、Claudio Magistris

  DOI：10.1055/s-2007-990813

  日期：2007.11

  General procedures are reported to prepare N-alkylureas, N,N'-dialkylureas (both symmetrical and unsymmetrical), and N,N,N'-trialkylureas by carbonylation of aliphatic amines, employing S,S-dimethyl dithiocarbonate (DMDTC) as a phosgene substitute. All reactions were carried out in water. Symmetrical disubstituted ureas were prepared directly working at 60 °C with a molar ratio of DMDTC:amine = 1:2

  据报道，通过脂肪胺的羰基化制备 N-烷基脲、N,N'-二烷基脲（对称和不对称）和 N,N,N'-三烷基脲的一般程序，采用 S,S-二硫代碳酸二甲酯 (DMDTC) 作为光气替代品。所有反应均在水中进行。在 60°C 下直接制备对称二取代脲，DMDTC: 胺的摩尔比 = 1:2，优选在氮气下。通过在室温下在第一步中选择性形成的 S-甲基 N-烷基-硫代氨基甲酸酯中间体分两步制备不对称脲。这些中间体在第二步中与氨或各种脂肪胺（伯胺和仲胺）在 50 至 70°C 的温度下发生反应。所有目标尿素均以高产率获得（28 个示例，平均收率 94%）和非常高的纯度（通常 >99.2%）。还需要注意的是回收工业利益的副产品甲硫醇，每摩尔 DMDTC 回收量为两摩尔，同时完全利用试剂。

表征谱图